Overall survival in cancer drug trials: New FDA draft guidance sets the barnews2025-08-25T18:20:37+00:00August 25th, 2025|Endpoints News|
Argenx’s Vyvgart clears Phase 3 in new subset of myasthenia gravis patientsnews2025-08-25T17:37:23+00:00August 25th, 2025|Endpoints News|
BeOne to get $885M upfront in royalty deal over Amgen’s Imdelltranews2025-08-25T16:02:36+00:00August 25th, 2025|Endpoints News|
AbbVie to buy psychedelic drug from partner Gilgameshnews2025-08-25T14:56:10+00:00August 25th, 2025|Endpoints News|
Merck looks to modest HIV business as a $5B underdognews2025-08-25T14:15:34+00:00August 25th, 2025|Endpoints News|
UK, drugmakers at odds over drug pricing plansnews2025-08-22T17:20:17+00:00August 22nd, 2025|Endpoints News|
Biohaven won’t face FDA advisory committee meeting for its SCA drugnews2025-08-22T15:43:44+00:00August 22nd, 2025|Endpoints News|
Obesity drug market hits turning point after lackluster results and lull in startupsnews2025-08-22T15:28:35+00:00August 22nd, 2025|Endpoints News|
CDC staff won’t serve as members of ACIP’s new Covid-19 working groupnews2025-08-21T19:49:54+00:00August 21st, 2025|Endpoints News|
AbbVie’s Rinvoq clears second Phase 3 trial in hair loss diseasenews2025-08-21T18:31:28+00:00August 21st, 2025|Endpoints News|
